Updated 14:15 GMT, 21 Nov 2026 SPX 6,910.39 -3.70% NDX 25,028.98 -5.61% VIX 35.89 +26.20% GOLD 3,515.40 -4.62% CL 83.98 +0.93% BTC 60,166.89 +2.33%
NAS100 25,029 −5.61% S&P 6,910 −3.70% GOLD $3,515 −4.62% BTC $60,167 +2.33% VIX 35.89 +26.20% latest tape · as of 14:15 UTC
The Screen · Healthcare · Biotechnology

Septerna, Inc.

SEPN · Nasdaq · USD · Market cap $1.9B · 130 employees

Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflammation, and metabolic diseases.

FAIL · Does not pass the screen
38.61 USD

Price as of 20 Nov 2026Daily close, not a live quote

Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed

Key facts today

  • Price38.61 USD at the 20 Nov 2026 close
  • Our value readUndervalued vs our fair value, as of 20 Nov 2026
  • Our regime readMarkup, as of 15 Nov 2026
  • Ethical screenDoes not pass
  • OptionsOpen interest leans to puts (put/call 1.39)
  • Last reviewed20 Nov 2026 (1 day ago)
  • Release timesRelease and earnings times on your chart: Event Guard Mentor

A summary of the dated readings below, not a live quote and not advice.

PRICE · ONE YEAR

Our fair-value range: $51.00 to $65.00, base estimate $60.00 (screen dated 2026-11-20).

Current read
Markup ?
Undervalued · screened 2026-11-20
  • Trend Markup
  • Insiders insiders sold, $807,015, latest filing 2026-11-12
  • Positioning no disclosures inside 60 days, left as found
  • Options put/call open interest 1.39, read 2026-11-20
  • Ethical does not pass the values gate
Price38.61 USD
Fair value60.00
Ethical score70.0/100
Value readUndervaluedas of 20 Nov 2026
Our investment reviews on this name
2026-11-16Read Markup42.60-9.4% to today Accumulation gives way to Markup after a 5% rise in 2 weeks
2026-10-30Read Accumulation40.41-4.5% to today Markdown gives way to Accumulation after a 13% rise in 3 weeks
2026-10-11Read Markdown35.67+8.2% to today Accumulation gives way to Markdown after an 8% slide in 9 days
2026-10-02Read Accumulation38.69-0.2% to today Markdown gives way to Accumulation while volume is distributing

Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.

The full research record, in depth, below
The Label · The Season, Not the Day

This name holds its markup label.

Septerna, Inc. holds its Markup at $38.61. Consolidating, no directional conviction, held for 329 days.

As held on the ledger · 2026-11-20
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 329 days
Price at the screen$38.61
ValuationN/A trailing · -25.81 forward price to earnings
Values screenFAIL · score 70.0
Beta2.20
The Workings

Five Screens: SEPN's Results

FAIL. Revenue purity

TestFigureLimitStatus
Business activity Permissible Permissible core business Pass
Debt load 3.96% Below 33% Pass
Interest-bearing cash 26.43% Below 33% Pass
Receivables 21.99% Below 49% Pass
Revenue purity 42.50% Below 5% Fail

Definitions, sources and threshold rules: ticker values-screen methodology.

The Ethical Read

Why It Falls Short, in Plain English

Septerna, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 43% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.

Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.

Follow this verdict

Get an email when SEPN's ethical verdict changes

Today SEPN does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.

Free, no account needed. Every email has a link to stop.

What the Numbers Say It Is Worth

The Fair Value Range

Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 36% discount to our $60.00 fair value.

Method.

51.00Conservative60.00Base case65.00Growth case 38.61Price

USD, 2026-11-20 screen. A 35.6% under base.

The Street's Range
51.00Street low 60.00Street average 65.00Street high 38.61Price

Street: 9 covering, consensus Strong Buy. Average target +55%.

Chart
The Business, in Plain Words

Early stage bet on unproven oral drugs

A promising lab compound only matters once it survives years of trials and reaches patients who can actually take it as a pill. Septerna sits at that early point, chasing GPCR targets in endocrinology and inflammation with nothing yet on the market. The opportunity rating sits at none despite the analyst target and the headline margin of safety, because the business remains pre-revenue in any meaningful sense and carries the classic clinical-stage uncertainties.

Revenue has jumped from a negligible base, yet the firm still posts a fifty percent negative profit margin and negative return on equity. The forward multiple looks extreme because there are no earnings to measure against. Strong buy ratings from nine analysts reflect hope rather than proof, and an unknown moat leaves the company exposed to larger players that can replicate or outspend.

Risk sits around the usual biotech traps of trial failure, repeated cash raises, and binary outcomes that can wipe out value overnight. Currency and regulatory shifts add further noise. Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-25.8x
EPS, trailing-1.30
EPS, forward-1.52
Revenue growth-12.2%revenue is shrinking
Profit margin-61.3%currently unprofitable
Return on equity-14.4%not currently earning a positive return on equity
FCF yield-0.42%
Debt to equity0.05minimal debt: a conservative balance sheet
Current ratio4.84comfortably covers its short-term bills
Beta2.20much more volatile than the market
Short interest, float0.13%
52-week range22.78 - 53.34
Market cap$1.9B
Employees130

SEPN-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.

Metric definitions and interpretation rules: ticker-page methodology.

The Dated Journal · Newest First, Never Edited

Every Entry, As Written

2026-11-20 Markup $39.20 -8.0% Entry 19
2026-11-16 Markup · changed $42.60 -12.8% Entry 18

The framework has shifted from accumulation to markup since the last review. Since the last review it dropped out of the Titan Ethical 500.

2026-11-09 Accumulation $48.85 +0.0% Entry 17
2026-11-08 Accumulation $48.85 +0.0% Entry 16
2026-11-07 Accumulation $48.85 +3.2% Entry 15
2026-11-06 Accumulation $47.35 -1.1% Entry 14
2026-11-05 Accumulation $47.88 +9.6% Entry 13
2026-11-04 Accumulation $43.70 -0.7% Entry 12
2026-11-03 Accumulation $44.00 +0.0% Entry 11
2026-11-02 Accumulation $44.00 +8.9% Entry 10

Earnings landed in this window. Ethical screening: FAIL.

Written on its date, before the outcome; never pruned.

Latest News · What the Market Is Reading on SEPN

Headlines from third-party outlets, linked for reference: not our reporting, not advice.

Related Securities · Others in SEPN's Space

Screened names in the same industry · explore each on its own page.

The Insider Ledger · Form 4 Filings, As Filed
Most recent filings · SEPN
DateInsiderTitleTypeSharesValue
2026-11-12 Finer Jeffrey CEO S - Sale+OE 18,500 $807,015
2026-11-11 Ezekowitz Alan Dir S - Sale 81,820 $3,934,363
2026-10-15 Bhatt Elizabeth Pres, COO S - Sale+OE 4,000 $149,644
2026-08-12 Third Rock Ventures V, L.P. 10% S - Sale 147,200 $7,399,858
2026-08-12 Ra Capital Management, L.P. Dir, 10% S - Sale 1,493,000 $63,452,500

Public filings, recorded as found. The full tape lives at Insider Intelligence.

What Holding Actually Paid · Price Plus Dividends
If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $23.57 +29.3% · $1,293 +29.3%
2 months $23.09 +32.0% · $1,320 +32.0%
3 months $26.44 +15.2% · $1,152 +15.2%
6 months $26.21 +16.3% · $1,163 +16.3%
1 year $10.28 +196.4% · $2,964 +196.4%

Historical returns from market close data. Past performance does not guarantee future results.

The Ledger's Promise

This entry now belongs to the ledger. Whatever SEPN does next, these words stay.

Septerna, Inc. · SEPN · Markup · $38.61
Recorded 2026-11-20 · before the outcome · scored mechanically

Membership

Thirteen thousand names carry this page. One desk keeps them honest.

Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.

Join the desk

Screening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.

Get our weekly market brief free.